Page last updated: 2024-11-02

oxidopamine and Paralysis

oxidopamine has been researched along with Paralysis in 1 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Paralysis: A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Guido, W1
Salinger, WL1

Other Studies

1 other study available for oxidopamine and Paralysis

ArticleYear
6-Hydroxydopamine treatment blocks the effects of chronic monocular paralysis in the cat's lateral geniculate nucleus.
    Brain research, 1989, Nov-06, Volume: 501, Issue:2

    Topics: Animals; Cats; Functional Laterality; Geniculate Bodies; Hydroxydopamines; Neuronal Plasticity; Oxid

1989